Login to Your Account



Viamet vanquishes yeast infections in phase IIb

By Michael Fitzhugh
Staff Writer

Monday, June 5, 2017

NEW ORLEANS – Viamet Pharmaceuticals Inc.'s lead fungal infection fighter, oral VT-1161, met the primary endpoint of a phase IIb trial in recurrent yeast infections, besting a placebo in all arms of the trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription